✦ LIBER ✦

A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease

✍ Scribed by Mariano, Caroline; Bosdet, Ian; Karsan, Aly; Ionescu, Diana; Murray, Nevin; Laskin, Janessa J.; Zhai, Yongliang; Melosky, Barbara; Sun, Sophie; Ho, Cheryl

Book ID: 121455171
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 609 KB
Volume: 83
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2013.10.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II clinical trial of celecoxib c

A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression

✍ Jun Zhao; Zhi-jie Wang; Jian-chun Duan; Qing-zhi Guo; Hua Bai; Lu Yang; Tong-ton 📂 Article 📅 2009 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 521 KB

Antitumor activity of the epidermal grow

Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Predictive value of ERCC1 and XPD polymo

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

✍ Shu-zhen Wei; Ping Zhan; Mei-qi Shi; Yi Shi; Qian Qian; Li-ke Yu; Yong Song 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 338 KB

2 Quality of life assessment in the elde

2 Quality of life assessment in the elderly population (above 70 years of age) with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with a platinum-based combination-chemotherapy regimen

✍ Bæksgaard, L.; Henriksen, A.; Hasselbalch, B.; Dandanell, J.; Perell, K.; Sørens 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Impact of treatment with bevacizumab bey

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

✍ Masayuki Takeda, Isamu Okamoto, Takeharu Yamanaka, Kazuhiko Nakagawa, Yoichi Nak 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 149 KB

Motexafin Gadolinium (MGd) is Active as

Motexafin Gadolinium (MGd) is Active as a Single Agent and in Combination with Pemetrexed and Docetaxel in Advanced Non–Small-Cell Lung Cancer (NSCLC) Patients who Failed Platinum-Based Chemotherapy: Early Results of 3 Phase II Trials

✍ R.B. Natale; G. Nicholas; K. Pandya; M. Edelman; S.C. Phan; M.F. Renschler 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 443 KB